ETON (Eton Pharmaceuticals) Debt-to-Equity : 0.27 (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Eton Pharmaceuticals Debt-to-Equity?

Eton Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $4.13 Mil. Eton Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.13 Mil. Eton Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $15.98 Mil. Eton Pharmaceuticals's debt to equity for the quarter that ended in Sep. 2024 was 0.27.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Eton Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

ETON' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.38 Max: 5.05
Current: 0.27

During the past 7 years, the highest Debt-to-Equity Ratio of Eton Pharmaceuticals was 5.05. The lowest was 0.00. And the median was 0.38.

ETON's Debt-to-Equity is ranked better than
50.97% of 826 companies
in the Drug Manufacturers industry
Industry Median: 0.27 vs ETON: 0.27

Eton Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Eton Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eton Pharmaceuticals Debt-to-Equity Chart

Eton Pharmaceuticals Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.43

0.46

0.38

0.50

0.35

Eton Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Equity	Get a 7-Day Free Trial															0.34	0.35	0.32	0.36	0.27

Competitive Comparison of Eton Pharmaceuticals's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Eton Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eton Pharmaceuticals's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eton Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Eton Pharmaceuticals's Debt-to-Equity falls into.

Eton Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Eton Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.38	+	0.022)	/	15.477
	=	0.35

Eton Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.125	+	0.126)	/	15.981
	=	0.27

Eton Pharmaceuticals (NAS:ETON) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Eton Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Eton Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Eton Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eton Pharmaceuticals Inc (NAS:ETON) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

21925 West Field Parkway, Suite 235, Deer Park, IL, USA, 60010-7278

Website

https://www.etonpharma.com

Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.

Executives

Opaleye Management Inc.	10 percent owner	ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
David Krempa	officer: Chief Business Officer	29125 W FIELD PARKWAY, SUITE 235, DEER PARK IL 60010
Sean Brynjelsen	director, officer: President & CEO	C/O ETON PHARMACEUTICALS, INC., 21925 W FIELD PKWY #235, DEER PARK IL 60010
James R. Gruber	officer: Chief Financial Officer	618 AMES STREET, LIBERTYVILLE IL 60048
William Wilson Troutman	officer: CFO, Treasurer & Secretary	21925 W FIELD PARKWAY, SUITE 235, DEER PARK IL 60010
Imprimis Pharmaceuticals, Inc.	10 percent owner	102 WOODMONT BLVD, SUITE 610, NASHVILLE TN 37215
Jennifer Mckie Adams	director	5410 TENNESSEE AVE, NASHVILLE TN 37209
Charles J Casamento	director	99 BELBROOK WAY, ATHERTON CA 94027
Norbert G Riedel	director	BAXTER INTERNATIONAL INC, ONE BAXTER PKWY DF2-1W, DEERFIELD IL 60015
Mark L Baum	director	C/O IMPRIMIS PHARMACEUTICALS, INC, 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130
Paul V Maier	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121